larotrectinib
E561035
breakthrough therapy
orphan drug
small molecule drug
targeted cancer therapy
tyrosine kinase inhibitor
Larotrectinib is a targeted cancer therapy that selectively inhibits TRK fusion proteins and is used to treat solid tumors harboring NTRK gene fusions regardless of tumor site.
All labels observed (1)
| Label | Occurrences |
|---|---|
| larotrectinib canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T6003721 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: larotrectinib Context triple: [Loxo Oncology, developedDrug, larotrectinib]
-
A.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
B.
Lynparza
Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
-
C.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
D.
Inflectra
Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
E.
Ibrance
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: larotrectinib Target entity description: Larotrectinib is a targeted cancer therapy that selectively inhibits TRK fusion proteins and is used to treat solid tumors harboring NTRK gene fusions regardless of tumor site.
-
A.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
B.
Lynparza
Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
-
C.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
D.
Inflectra
Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
E.
Ibrance
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
breakthrough therapy
ⓘ
orphan drug ⓘ small molecule drug ⓘ targeted cancer therapy ⓘ tyrosine kinase inhibitor ⓘ |
| approvedBy |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| blackBoxWarning | no boxed warning in U.S. labeling as of initial approval ⓘ |
| coDeveloper | Bayer NERFINISHED ⓘ |
| commonAdverseEffect |
dizziness
ⓘ
fatigue ⓘ increased liver enzymes ⓘ nausea ⓘ vomiting ⓘ |
| developer | Loxo Oncology NERFINISHED ⓘ |
| dosageForm |
oral capsules
ⓘ
oral solution ⓘ |
| eliminationRoute |
feces
ⓘ
urine ⓘ |
| firstFDAApprovalDate | 2018-11 ⓘ |
| hasATCCode | L01EX09 ⓘ |
| hasCASNumber | 1223405-08-0 ⓘ |
| hasClinicalTrial |
NCT02122913
ⓘ
NCT02576431 ⓘ NCT02637687 ⓘ |
| hasINN | larotrectinib NERFINISHED ⓘ |
| hasIUPACName | (3R)-N-{5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyridin-3-yl}-3-(1H-1,2,4-triazol-1-yl)pyrrolidine-1-carboxamide ⓘ |
| hasMolecularFormula | C21H22F2N6O ⓘ |
| hasMolecularWeight | molar mass about 380.4 g/mol ⓘ |
| hasTradeName | Vitrakvi NERFINISHED ⓘ |
| indication |
treatment of metastatic solid tumors with NTRK gene fusions
ⓘ
treatment of solid tumors with NTRK gene fusions ⓘ treatment of unresectable solid tumors with NTRK gene fusions ⓘ tumor-agnostic cancer therapy for NTRK fusion–positive tumors ⓘ |
| isTumorAgnostic | true ⓘ |
| legalStatusEU | prescription only ⓘ |
| legalStatusUS | prescription only ⓘ |
| mechanismOfAction | selective inhibitor of tropomyosin receptor kinase (TRK) fusion proteins ⓘ |
| metabolism | primarily metabolized by CYP3A4 ⓘ |
| pregnancyCategory | can cause fetal harm based on mechanism and animal data ⓘ |
| requiresBiomarker | NTRK gene fusion ⓘ |
| routeOfAdministration | oral ⓘ |
| selectivity | highly selective for TRK over other kinases ⓘ |
| targets |
NTRK1 gene fusion proteins
ⓘ
NTRK2 gene fusion proteins ⓘ NTRK3 gene fusion proteins ⓘ TRKA ⓘ TRKB NERFINISHED ⓘ TRKC NERFINISHED ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: larotrectinib Description of subject: Larotrectinib is a targeted cancer therapy that selectively inhibits TRK fusion proteins and is used to treat solid tumors harboring NTRK gene fusions regardless of tumor site.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject surface form:
Loxo Oncology
subject surface form:
Loxo Oncology